商业化的胸苷激酶 1 检测在 42 例住院马淋巴瘤诊断中的临床性能（2017-2020 年）。

Clinical performance of a commercially available thymidine kinase 1 assay for diagnosis of lymphoma in 42 hospitalized horses (2017-2020).

机构信息

Department of Clinical Studies, University of Pennsylvania, Kennett Square, Pennsylvania, USA.

Large Animal Clinical Sciences, University of Florida College of Veterinary Medicine, Gainesville, Florida, USA.

出版信息

J Vet Intern Med. 2021 Sep;35(5):2495-2499. doi: 10.1111/jvim.16239. Epub 2021 Aug 6.

DOI:10.1111/jvim.16239

PMID:34359096

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8478028/

Abstract

BACKGROUND

Antemortem definitive diagnosis of lymphoma in horses is often difficult. Thymidine kinase 1 (TK1) assay is a potentially useful biomarker for lymphoma in horses.

HYPOTHESIS/OBJECTIVES: To report the clinical performance of a commercially available TK1 assay for diagnosis of lymphoma in horses. We hypothesized that there would be no association between serum TK1 activity and a diagnosis of lymphoma in horses.

ANIMALS

Forty-two hospitalized horses, 14 with a definitive diagnosis of lymphoma, 4 with other neoplasia, and 24 with inflammatory disease.

METHODS

Retrospective medical record review, groups were compared via Kruskal-Wallis and Mann-Whitney tests, and logistic regression was performed.

RESULTS

Median (range) TK1 was 3 U/L (0.4-17.7 U/L) in horses with lymphoma and 3.9 U/L (0.8-94 U/L) in horses without lymphoma (P = .59). There was no significant difference in total protein between horses with and without lymphoma (6.6 g/dL [5.5-8.3 g/dL] vs 6.6 g/dL [4.7-10.4 g/dL]; P = .83). There was no significant difference in fibrinogen between horses with and without lymphoma (447 [100-1364] mg/dL vs 433 [291-2004] mg/dL; P = .47). On logistic regression, serum TK1 activity was not associated with a diagnosis of lymphoma (odds ratio, 0.97; 95% confidence interval, 0.9-1.05, P = .48).

CONCLUSION AND CLINICAL IMPORTANCE

Serum TK1 values were not predictive of lymphoma diagnosis in this cohort of horses.

摘要

背景

马的淋巴瘤生前明确诊断往往较为困难。胸苷激酶 1（TK1）检测可能是一种有用的马淋巴瘤生物标志物。

假设/目的：报告一种商用 TK1 检测方法用于诊断马淋巴瘤的临床性能。我们假设马的血清 TK1 活性与淋巴瘤诊断之间没有关联。

动物

42 匹住院马，14 匹有明确的淋巴瘤诊断，4 匹有其他肿瘤，24 匹有炎症性疾病。

方法

回顾性病历审查，通过 Kruskal-Wallis 和 Mann-Whitney 检验比较各组，进行逻辑回归分析。

结果

患有淋巴瘤的马的 TK1 中位数（范围）为 3 U/L（0.4-17.7 U/L），而没有淋巴瘤的马的 TK1 中位数（范围）为 3.9 U/L（0.8-94 U/L）（P=0.59）。患有和未患有淋巴瘤的马的总蛋白之间无显著差异（6.6 g/dL[5.5-8.3 g/dL]与 6.6 g/dL[4.7-10.4 g/dL]；P=0.83）。患有和未患有淋巴瘤的马的纤维蛋白原之间无显著差异（447 [100-1364] mg/dL 与 433 [291-2004] mg/dL；P=0.47）。在逻辑回归中，血清 TK1 活性与淋巴瘤诊断无关（比值比，0.97；95%置信区间，0.9-1.05，P=0.48）。